Peptide Library

Human study PLS-00142

Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.

Case-control study · 80 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.primary · The Egyptian journal of immunology · 2022-04-01 · PMID 35436057 · DOI

Design and participants

Design
Case-control study
Population
Egyptian patients with nonalcoholic fatty liver disease (n=40) and a control group (n=40)
Conditions
Non-alcoholic fatty liver disease, Metabolic syndrome, Insulin resistance
Planned enrollment (registry)
Not reported
Enrolled
80
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Serum Tβ4 was lower in NAFLD patients and correlated with metabolic markers. The authors concluded it could serve as a biomarker for diagnosing NAFLD.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta 4 was only measured as an endogenous serum biomarker and was never administered to participants.
    • abstract only: Only the PubMed abstract is available, so methods, recruitment and analysis details cannot be checked.
    • small or imprecise: Only 80 participants (40 cases, 40 controls), and the reported perfect diagnostic accuracy is likely optimistic.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 35436057, abstract (final sentence) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 35436057, abstract (sentences 5-7) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 35436057, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 35436057, title (title) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).